AZ’s Tricky Balancing Act On Non-Profit COVID Vaccine
Hopeful Of Read-Out Before 2020 Ends
AstraZeneca is developing a COVID-19 vaccine as a “public health emergency not a commercial opportunity” but has to maintain its business growth plans at the same time.
You may also be interested in...
Pfizer is unlikely to tie up with Indian companies soon for manufacture of its COVID-19 vaccine as it has built capacity for the first phase. However, as discussions to supply to the COVAX facility and developing countries progress, it could evaluate such opportunities later.
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.